Mingting Liang1,2, Ying Pang2, Shuguang Zhang3, Mei Zhang4. 1. Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China. 2. Department of Cardiology, Liaocheng City People's Hospital, Liaocheng, Shandong, China. 3. Department of Laboratory, Liaocheng City People's Hospital, Liaocheng, Shandong, China. 4. Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China. daixh@vip.sina.com.
Abstract
OBJECTIVE: The goal of this study was to determine plasma levels of hepatocyte growth factor (HGF) in patients with pulmonary artery hypertension (PAH), and to explore the diagnostic value of plasma HGF for PAH. METHODS: Sixty subjects were divided into a control group of healthy individuals (N = 15) and a PAH group (N = 45). The PAH group was divided into three groups (N = 15 each) according to disease severity: mild PAH (group L), moderate PAH (group M), and severe PAH (group H). Plasma HGF levels in PAH patients were collected on the morning after admission to the hospital. Mean pulmonary arterial pressure was measured by right heart catheterization. RESULTS: Plasma HGF levels were significantly higher in the PAH group than in the control group (P < 0.001), and significantly higher in group H than in group M (P < 0.001) and group L (P < 0.001). There was no statistically significant difference in plasma HGF levels between patients with PAH of idiopathic etiology and those with PAH of secondary etiology (P = 0.595). The HGF level was positively correlated with mean pulmonary arterial pressure (Pearson correlation coefficient 0.967, P < 0.001). CONCLUSION: Plasma levels of HGF in PAH patients with mild disease were significantly higher than those in healthy controls, suggesting that plasma HGF has potential utility as a diagnostic biomarker for early PAH.
OBJECTIVE: The goal of this study was to determine plasma levels of hepatocyte growth factor (HGF) in patients with pulmonary artery hypertension (PAH), and to explore the diagnostic value of plasma HGF for PAH. METHODS: Sixty subjects were divided into a control group of healthy individuals (N = 15) and a PAH group (N = 45). The PAH group was divided into three groups (N = 15 each) according to disease severity: mild PAH (group L), moderate PAH (group M), and severe PAH (group H). Plasma HGF levels in PAH patients were collected on the morning after admission to the hospital. Mean pulmonary arterial pressure was measured by right heart catheterization. RESULTS: Plasma HGF levels were significantly higher in the PAH group than in the control group (P < 0.001), and significantly higher in group H than in group M (P < 0.001) and group L (P < 0.001). There was no statistically significant difference in plasma HGF levels between patients with PAH of idiopathic etiology and those with PAH of secondary etiology (P = 0.595). The HGF level was positively correlated with mean pulmonary arterial pressure (Pearson correlation coefficient 0.967, P < 0.001). CONCLUSION: Plasma levels of HGF in PAH patients with mild disease were significantly higher than those in healthy controls, suggesting that plasma HGF has potential utility as a diagnostic biomarker for early PAH.
Authors: Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2009-01-22 Impact factor: 21.405
Authors: Kathrin Rychli; Bernhard Richter; Philipp J Hohensinner; Ali Kariem Mahdy; Stephanie Neuhold; Gerlinde Zorn; Rudolf Berger; Deddo Mörtl; Kurt Huber; Richard Pacher; Johann Wojta; Alexander Niessner; Martin Hülsmann Journal: Heart Date: 2011-05-14 Impact factor: 5.994
Authors: Georgios Giannakoulas; Konstantinos Dimopoulos; Aidan P Bolger; Edgar Lik Tay; Ryo Inuzuka; Elisabeth Bedard; Constantinos Davos; Lorna Swan; Michael A Gatzoulis Journal: Am J Cardiol Date: 2010-03-15 Impact factor: 2.778
Authors: Y Taniyama; R Morishita; M Aoki; H Nakagami; K Yamamoto; K Yamazaki; K Matsumoto; T Nakamura; Y Kaneda; T Ogihara Journal: Gene Ther Date: 2001-02 Impact factor: 5.250
Authors: Laura C Price; Gaetano Caramori; Frederic Perros; Chao Meng; Natalia Gambaryan; Peter Dorfmuller; David Montani; Paolo Casolari; Jie Zhu; Konstantinos Dimopoulos; Dongmin Shao; Barbara Girerd; Sharon Mumby; Alastair Proudfoot; Mark Griffiths; Alberto Papi; Marc Humbert; Ian M Adcock; S John Wort Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240